Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
Russell, Stephen, Bennett, Jean, Wellman, Jennifer A, Chung, Daniel C, Yu, Zi-Fan, Tillman, Amy, Wittes, Janet, Pappas, Julie, Elci, Okan, McCague, Sarah, Cross, Dominique, Marshall, Kathleen A, WalshМова:
english
Журнал:
The Lancet
DOI:
10.1016/S0140-6736(17)31868-8
Date:
July, 2017
Файл:
PDF, 1.34 MB
english, 2017
File converter
Більше результатів пошуку
More benefits 
